AF
PACB icon

Avanza Fonder’s Pacific Biosciences PACB Stock Holding History

Avanza Fonder’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-80,727
Closed -$103K – 469
2025
Q1 		$103K Buy
80,727
+4,319
+6% +$6.63K ﹤0.01% 436
2024
Q4 		$140K Buy
+76,408
New +$149K ﹤0.01% 413

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avanza Fonder's PACB Position: Q2 2025 in Review

Avanza Fonder sold out of Pacific Biosciences (PACB) in Q2 2025, closing a stake of 80,727 shares — an estimated $103K sold.

Avanza Fonder first reported a position in PACB in Q4 2024 and held it in 2 quarters. The position peaked at $140K in Q4 2024. 207 funds tracked by Wall St. Rank hold PACB as of Q2 2025.

  • Avanza Fonder reported no remaining Pacific Biosciences position as of Q2 2025 after selling out during the quarter.
  • Avanza Fonder sold 80,727 Pacific Biosciences shares in Q2 2025, an estimated $103K.
  • Avanza Fonder first reported a position in Pacific Biosciences in Q4 2024 and held it in 2 quarters.
  • Avanza Fonder's Pacific Biosciences position peaked at $140K in Q4 2024.
  • 207 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2025.

Based on Avanza Fonder's 13F filing for Q2 2025, filed 14 Jul 2025.